1
|
Carrión B, Liu Y, Hadi M, Lundstrom J, Christensen JR, Ammitzbøll C, Dziegiel MH, Sørensen PS, Comabella M, Montalban X, Sellebjerg F, Issazadeh-Navikas S. Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2021; 8:8/6/e1065. [PMID: 34385365 PMCID: PMC8362604 DOI: 10.1212/nxi.0000000000001065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 06/16/2021] [Indexed: 11/15/2022]
Abstract
BACKGROUND AND OBJECTIVE The aim of this study was to determine whether natural killer T (NKT) cells, including invariant (i) NKT cells, have clinical value in preventing the progression of multiple sclerosis (MS) by examining the mechanisms by which a distinct self-peptide induces a novel, protective invariant natural killer T cell (iNKT cell) subset. METHODS We performed a transcriptomic and functional analysis of iNKT cells that were reactive to a human collagen type II self-peptide, hCII707-721, measuring differentially induced genes, cytokines, and suppressive capacity. RESULTS We report the first transcriptomic profile of human conventional vs novel hCII707-721-reactive iNKT cells. We determined that hCII707-721 induces protective iNKT cells that are found in the blood of healthy individuals but not progressive patients with MS (PMS). By transcriptomic analysis, we observed that hCII707-721 promotes their development and proliferation, favoring the splicing of full-length AKT serine/threonine kinase 1 (AKT1) and effector function of this unique lineage by upregulating tumor necrosis factor (TNF)-related genes. Furthermore, hCII707-721-reactive iNKT cells did not upregulate interferon (IFN)-γ, interleukin (IL)-4, IL-10, IL-13, or IL-17 by RNA-seq or at the protein level, unlike the response to the glycolipid alpha-galactosylceramide. hCII707-721-reactive iNKT cells increased TNFα only at the protein level and suppressed autologous-activated T cells through FAS-FAS ligand (FAS-FASL) and TNFα-TNF receptor I signaling but not TNF receptor II. DISCUSSION Based on their immunomodulatory properties, NKT cells have a potential value in the treatment of autoimmune diseases, such as MS. These significant findings suggest that endogenous peptide ligands can be used to expand iNKT cells, without causing a cytokine storm, constituting a potential immunotherapy for autoimmune conditions, including PMS.
Collapse
Affiliation(s)
- Belinda Carrión
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Yawei Liu
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Mahdieh Hadi
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Jon Lundstrom
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Jeppe Romme Christensen
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Cecilie Ammitzbøll
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Morten Hanefeld Dziegiel
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Per Soelberg Sørensen
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Manuel Comabella
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Xavier Montalban
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Finn Sellebjerg
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark
| | - Shohreh Issazadeh-Navikas
- From the Biotech Research and Innovation Centre (BRIC) (B.C., Y.L., M.H., J.L., S.I.-N.), University of Copenhagen; Danish Multiple Sclerosis Center (J.R.C., C.A., P.S.S.), University of Copenhagen and Department of Neurology, Rigshospitalet; Blood Bank (M.H.D.), Copenhagen University Hospital, Denmark; Centre d'Esclerosi Múltiple de Catalunya (M.C.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Barcelona, Spain; and Centre d'Esclerosi Múltiple de Catalunya (X.M.), Cemcat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d´Hebron (HUVH) - Universitat Autònoma de Barcelona, Spain; Danish Multiple Sclerosis Center, University of Copenhagen and Department of Neurology, Rigshospitalet, Denmark.
| |
Collapse
|
2
|
Abstract
Invariant natural killer T (iNKT) cells are involved in various autoimmune diseases. Although iNKT cells are arthritogenic, transforming growth factor beta (TGFβ)-treated tolerogenic peritoneal macrophages (Tol-pMφ) from wild-type (WT) mice are more tolerogenic than those from CD1d knock-out iNKT cell-deficient mice in a collagen-induced arthritis (CIA) model. The underlying mechanism by which pMφ can act as tolerogenic antigen presenting cells (APCs) is currently unclear. To determine cellular mechanisms underlying CD1d-dependent tolerogenicity of pMφ, in vitro and in vivo characteristics of pMφ were investigated. Unlike dendritic cells or splenic Mφ, pMφ from CD1d+/− mice showed lower expression levels of costimulatory molecule CD86 and produced lower amounts of inflammatory cytokines upon lipopolysaccharide (LPS) stimulation compared to pMφ from CD1d-deficient mice. In a CIA model of CD1d-deficient mice, adoptively transferred pMφ from WT mice reduced the severity of arthritis. However, pMφ from CD1d-deficient mice were unable to reduce the severity of arthritis. Hence, the tolerogenicity of pMφ is a cell-intrinsic property that is probably confer-red by iNKT cells during pMφ development rather than by interactions of pMφ with iNKT cells during antigen presentation to cognate T cells.
Collapse
Affiliation(s)
- Fathihah Basri
- Department of Life Sciences, Korea University, Seoul 02841, Korea
| | - Sundo Jung
- Department of Biomedical Laboratory Science, Shinhan University, Uijeongbu 11644, Korea
| | - Se Hoon Park
- Department of Life Sciences, Korea University, Seoul 02841, Korea
| | - Se-Ho Park
- Department of Life Sciences, Korea University, Seoul 02841, Korea
| |
Collapse
|
3
|
Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, Louis C. Natural killer cells in inflammatory autoimmune diseases. Clin Transl Immunology 2021; 10:e1250. [PMID: 33552511 PMCID: PMC7850912 DOI: 10.1002/cti2.1250] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 01/11/2021] [Accepted: 01/14/2021] [Indexed: 12/12/2022] Open
Abstract
Natural killer (NK) cells are a specialised population of innate lymphoid cells (ILCs) that help control local immune responses. Through natural cytotoxicity, production of cytokines and chemokines, and migratory capacity, NK cells play a vital immunoregulatory role in the initiation and chronicity of inflammatory and autoimmune responses. Our understanding of their functional differences and contributions in disease settings is evolving owing to new genetic and functional murine proof-of-concept studies. Here, we summarise current understanding of NK cells in several classic autoimmune disorders, particularly in rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and type 1 diabetes mellitus (T1DM), but also less understood diseases such as idiopathic inflammatory myopathies (IIMs). A better understanding of how NK cells contribute to these autoimmune disorders may pave the way for NK cell-targeted therapeutics.
Collapse
Affiliation(s)
- Yuyan Yang
- Tsinghua University School of Medicine Beijing China.,Inflammation Division The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia
| | - Jessica Day
- Inflammation Division The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia.,Medical Biology University of Melbourne Melbourne VIC Australia.,Rheumatology Unit The Royal Melbourne Hospital Parkville VIC Australia
| | | | - Ian P Wicks
- Inflammation Division The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia.,Medical Biology University of Melbourne Melbourne VIC Australia.,Rheumatology Unit The Royal Melbourne Hospital Parkville VIC Australia
| | - Cynthia Louis
- Inflammation Division The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia.,Medical Biology University of Melbourne Melbourne VIC Australia
| |
Collapse
|
4
|
Abstract
Inflammatory arthritis (IA) refers to a group of chronic diseases, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and other spondyloarthritis (SpA). IA is characterized by autoimmune-mediated joint inflammation and is associated with inflammatory cytokine networks. Innate lymphocytes, including innate-like lymphocytes (ILLs) expressing T or B cell receptors and innate lymphoid cells (ILCs), play important roles in the initiation of host immune responses against self-antigens and rapidly produce large amounts of cytokines upon stimulation. TNF (Tumor Necrosis Factor)-α, IFN (Interferon)-γ, Th2-related cytokines (IL-4, IL-9, IL-10, and IL-13), IL-17A, IL-22, and GM-CSF are involved in IA and are secreted by ILLs and ILCs. In this review, we focus on the current knowledge of ILL and ILC phenotypes, cytokine production and functions in IA. A better understanding of the roles of ILLs and ILCs in IA initiation and development will ultimately provide insights into developing effective strategies for the clinical treatment of IA patients.
Collapse
Affiliation(s)
- Xunyao Wu
- The Ministry of Education Key Laboratory, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
5
|
Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2020; 20:358-365. [PMID: 32234294 DOI: 10.1016/j.clml.2020.01.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Revised: 01/16/2020] [Accepted: 01/16/2020] [Indexed: 12/28/2022]
Abstract
Multiple myeloma (MM) is an incurable B-cell malignancy. The immunotherapeutic approach for MM therapy is evolving. The Cd1d/invariant natural killer T-cell/glycolipid immune axis belongs to the innate immunity, and we have highlighted role in myeloma pathogenesis in the present study. The recent development of the chimeric antigen receptor (CAR19)-invariant natural killer T-cells resulted in our renewed interest in this immune system and offer new perspectives for future anti-MM immunotherapies.
Collapse
|
6
|
Lee B, Jo Y, Kim G, Ali LA, Sohn DH, Lee SG, Kim K, Shin E, Ryu SH, Hong C. Specific Inhibition of Soluble γc Receptor Attenuates Collagen-Induced Arthritis by Modulating the Inflammatory T Cell Responses. Front Immunol 2019; 10:209. [PMID: 30800133 PMCID: PMC6375885 DOI: 10.3389/fimmu.2019.00209] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 01/24/2019] [Indexed: 11/14/2022] Open
Abstract
IL-17 produced by Th17 cells has been implicated in the pathogenesis of rheumatoid arthritis (RA). It is important to prevent the differentiation of Th17 cells in RA. Homodimeric soluble γc (sγc) impairs IL-2 signaling and enhances Th17 differentiation. Thus, we aimed to block the functions of sγc by inhibiting the formation of homodimeric sγc. The homodimeric form of sγc was strikingly disturbed by sγc-binding DNA aptamer. Moreover, the aptamer effectively inhibited Th17 cell differentiation and restored IL-2 and IL-15 signaling impaired by sγc with evidences of increased survival of T cells. sγc was highly expressed in SF of RA patients and increased in established CIA mice. The therapeutic effect of PEG-aptamer was tested in CIA model and its treatment alleviated arthritis pathogenesis with impaired differentiation of pathogenic Th17, NKT1, and NKT17 cells in inflamed joint. Homodimeric sγc has pathogenic roles to exacerbate RA progression with differentiation of local Th17, NKT1, and NKT17 cells. Therefore, sγc is suggested as target of a therapeutic strategy for RA.
Collapse
Affiliation(s)
- Byunghyuk Lee
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, South Korea
| | - Yuna Jo
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, South Korea
| | - Geona Kim
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, South Korea
| | - Laraib Amir Ali
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, South Korea
| | - Dong Hyun Sohn
- Department of Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, South Korea
| | - Seung-Geun Lee
- Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea
| | - Kiseok Kim
- Aptamer Sciences Inc., POSTECH Biotech Center, Pohang, South Korea
| | - Euisu Shin
- Aptamer Sciences Inc., POSTECH Biotech Center, Pohang, South Korea
| | - Sung Ho Ryu
- Department of Life Sciences, Pohang University of Science and Technology, Pohang, South Korea
| | - Changwan Hong
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, South Korea
| |
Collapse
|
7
|
Kritikou E, van Duijn J, Nahon JE, van der Heijden T, Bouwman M, Groeneveldt C, Schaftenaar FH, Kröner MJ, Kuiper J, van Puijvelde GH, Bot I. Disruption of a CD1d-mediated interaction between mast cells and NKT cells aggravates atherosclerosis. Atherosclerosis 2019; 280:132-139. [DOI: 10.1016/j.atherosclerosis.2018.11.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 10/10/2018] [Accepted: 11/13/2018] [Indexed: 12/12/2022]
|
8
|
Natural killer T cells in Preeclampsia: An updated review. Biomed Pharmacother 2017; 95:412-418. [DOI: 10.1016/j.biopha.2017.08.077] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Revised: 08/19/2017] [Accepted: 08/19/2017] [Indexed: 12/13/2022] Open
|
9
|
Lan P, Fan Y, Zhao Y, Lou X, Monsour HP, Zhang X, Choi Y, Dou Y, Ishii N, Ghobrial RM, Xiao X, Li XC. TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury. J Clin Invest 2017; 127:2222-2234. [PMID: 28436935 DOI: 10.1172/jci91075] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 02/23/2017] [Indexed: 12/16/2022] Open
Abstract
Tissue-resident immune cells play a key role in local and systemic immune responses. The liver, in particular, hosts a large number of invariant natural killer T (iNKT) cells, which are involved in diverse immune responses. However, the mechanisms that regulate survival and homeostasis of liver iNKT cells are poorly defined. Here we have found that liver iNKT cells constitutively express the costimulatory TNF superfamily receptor OX40 and that OX40 stimulation results in massive pyroptotic death of iNKT cells, characterized by the release of potent proinflammatory cytokines that induce liver injury. This OX40/NKT pyroptosis pathway also plays a key role in concanavalin A-induced murine hepatitis. Mechanistically, we demonstrated that liver iNKT cells express high levels of caspase 1 and that OX40 stimulation activates caspase 1 via TNF receptor-associated factor 6-mediated recruitment of the paracaspase MALT1. We also found that activation of caspase 1 in iNKT cells results in processing of pro-IL-1β to mature IL-1β as well as cleavage of the pyroptotic protein gasdermin D, which generates a membrane pore-forming fragment to produce pyroptotic cell death. Thus, our study has identified OX40 as a death receptor for iNKT cells and uncovered a molecular mechanism of pyroptotic cell death. These findings may have important clinical implications in the development of OX40-directed therapies.
Collapse
Affiliation(s)
- Peixiang Lan
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Yihui Fan
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Yue Zhao
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Xiaohua Lou
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Howard P Monsour
- Department of Medicine, Division of Hepatology, Houston Methodist Hospital, Texas Medical Center, Houston, Texas, USA
| | - Xiaolong Zhang
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Yongwon Choi
- University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Yaling Dou
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Naoto Ishii
- Department of Microbiology and Immunology, Tohoku University School of Medicine, Sendai, Japan
| | - Rafik M Ghobrial
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and.,Department of Surgery, Weill Cornell Medical College of Cornell University, New York, New York, USA
| | - Xiang Xiao
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and
| | - Xian Chang Li
- Immunobiology and Transplant Science Center, Houston Methodist Research Institute, and.,Department of Surgery, Weill Cornell Medical College of Cornell University, New York, New York, USA
| |
Collapse
|
10
|
Effects of Invariant NKT Cells on Parasite Infections and Hygiene Hypothesis. J Immunol Res 2016; 2016:2395645. [PMID: 27563682 PMCID: PMC4987483 DOI: 10.1155/2016/2395645] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2016] [Accepted: 06/20/2016] [Indexed: 01/08/2023] Open
Abstract
Invariant natural killer T (iNKT) cells are unique subset of innate-like T cells recognizing glycolipids. iNKT cells can rapidly produce copious amounts of cytokines upon antigen stimulation and exert potent immunomodulatory activities for a wide variety of immune responses and diseases. We have revealed the regulatory effect of iNKT cells on autoimmunity with a serial of publications. On the other hand, the role of iNKT cells in parasitic infections, especially in recently attractive topic “hygiene hypothesis,” has not been clearly defined yet. Bacterial and parasitic cell wall is a cellular structure highly enriched in a variety of glycolipids and lipoproteins, some of which may serve as natural ligands of iNKT cells. In this review, we mainly summarized the recent findings on the roles and underlying mechanisms of iNKT cells in parasite infections and their cross-talk with Th1, Th2, Th17, Treg, and innate lymphoid cells. In most cases, iNKT cells exert regulatory or direct cytotoxic roles to protect hosts against parasite infections. We put particular emphasis as well on the identification of the natural ligands from parasites and the involvement of iNKT cells in the hygiene hypothesis.
Collapse
|
11
|
Jin HM, Kee SJ, Cho YN, Kang JH, Kim MJ, Jung HJ, Park KJ, Kim TJ, Lee SI, Choi H, Koh JT, Kim N, Park YW. Dysregulated osteoclastogenesis is related to natural killer T cell dysfunction in rheumatoid arthritis. Arthritis Rheumatol 2016; 67:2639-50. [PMID: 26097058 DOI: 10.1002/art.39244] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Accepted: 06/09/2015] [Indexed: 01/15/2023]
Abstract
OBJECTIVE To investigate the role played by natural killer T (NKT) cells in osteoclastogenesis and their effects on inflammatory bone destruction. METHODS Patients with rheumatoid arthritis (RA) (n = 25) and healthy controls (n = 12) were enrolled in this study. In vitro osteoclastogenesis experiments were performed using peripheral blood mononuclear cells (PBMCs) in the presence of macrophage colony-stimulating factor and RANKL. PBMCs were cultured in vitro with α-galactosylceramide (αGalCer), and proliferation indices of NKT cells were estimated by flow cytometry. In vivo effects of αGalCer-stimulated NKT cells on inflammation and bone destruction were determined in mice with collagen-induced arthritis. RESULTS In vitro osteoclastogenesis was found to be significantly inhibited by αGalCer in healthy controls but not in RA patients. Proliferative responses of NKT cells and STAT-1 phosphorylation in monocytes in response to αGalCer were impaired in RA patients. Notably, αGalCer-stimulated NKT cells inhibited osteoclastogenesis mainly via interferon-γ production in a cytokine-dependent manner (not by cell-cell contact) and down-regulated osteoclast-associated genes. Mice treated with αGalCer showed less severe arthritis and reduced bone destruction. Moreover, proinflammatory cytokine expression in arthritic joints was found to be reduced by αGalCer treatment. CONCLUSION This study primarily demonstrates that αGalCer-stimulated NKT cells have a regulatory effect on osteoclastogenesis and a protective effect against inflammatory bone destruction. However, it also shows that these effects of αGalCer are diminished in RA patients and that this is related to NKT cell dysfunction. These findings provide important information for those searching for novel therapeutic strategies to prevent bone destruction in RA.
Collapse
Affiliation(s)
- Hye-Mi Jin
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Seung-Jung Kee
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Young-Nan Cho
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Jeong-Hwa Kang
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Moon-Ju Kim
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Hyun-Ju Jung
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Ki-Jeong Park
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Tae-Jong Kim
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| | - Sang-Il Lee
- Gyeongsang National University School of Medicine, Gyeongnam, Republic of Korea
| | - Hyuck Choi
- Chonnam National University School of Dentistry, Gwangju, Republic of Korea
| | - Jeong-Tae Koh
- Chonnam National University School of Dentistry, Gwangju, Republic of Korea
| | - Nacksung Kim
- Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Yong-Wook Park
- Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
| |
Collapse
|
12
|
Mansour S, Tocheva AS, Sanderson JP, Goulston LM, Platten H, Serhal L, Parsons C, Edwards MH, Woelk CH, Elkington PT, Elliott T, Cooper C, Edwards CJ, Gadola SD. Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid Arthritis. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2015; 195:5582-91. [PMID: 26553073 PMCID: PMC4671310 DOI: 10.4049/jimmunol.1501092] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 10/09/2015] [Indexed: 11/19/2022]
Abstract
Invariant NKT cells (iNKT) are potent immunoregulatory T cells that recognize CD1d via a semi-invariant TCR (iNKT-TCR). Despite the knowledge of a defective iNKT pool in several autoimmune conditions, including rheumatoid arthritis (RA), a clear understanding of the intrinsic mechanisms, including qualitative and structural changes of the human iNKT repertoire at the earlier stages of autoimmune disease, is lacking. In this study, we compared the structure and function of the iNKT repertoire in early RA patients with age- and gender-matched controls. We analyzed the phenotype and function of the ex vivo iNKT repertoire as well as CD1d Ag presentation, combined with analyses of a large panel of ex vivo sorted iNKT clones. We show that circulating iNKTs were reduced in early RA, and their frequency was inversely correlated to disease activity score 28. Proliferative iNKT responses were defective in early RA, independent of CD1d function. Functional iNKT alterations were associated with a skewed iNKT-TCR repertoire with a selective reduction of high-affinity iNKT clones in early RA. Furthermore, high-affinity iNKTs in early RA exhibited an altered functional Th profile with Th1- or Th2-like phenotype, in treatment-naive and treated patients, respectively, compared with Th0-like Th profiles exhibited by high-affinity iNKTs in controls. To our knowledge, this is the first study to provide a mechanism for the intrinsic qualitative defects of the circulating iNKT clonal repertoire in early RA, demonstrating defects of iNKTs bearing high-affinity TCRs. These defects may contribute to immune dysregulation, and our findings could be exploited for future therapeutic intervention.
Collapse
Affiliation(s)
- Salah Mansour
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, United Kingdom;
| | - Anna S Tocheva
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
| | | | - Lyndsey M Goulston
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, United Kingdom; National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Helen Platten
- National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Lina Serhal
- National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Camille Parsons
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Mark H Edwards
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, United Kingdom; National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Christopher H Woelk
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Paul T Elkington
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Tim Elliott
- Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, United Kingdom; Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom
| | - Cyrus Cooper
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, United Kingdom; National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom; Oxford National Institute for Health Research Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7HE, United Kingdom; and
| | - Christopher J Edwards
- Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, United Kingdom; National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom; Oxford National Institute for Health Research Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7HE, United Kingdom; and
| | - Stephan D Gadola
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom; National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton, Southampton SO16 6YD, United Kingdom; Novartis Institutes of Biomedical Research, 4002 Basel, Switzerland
| |
Collapse
|
13
|
Fjelbye J, Antvorskov JC, Buschard K, Issazadeh-Navikas S, Engkilde K. CD1d knockout mice exhibit aggravated contact hypersensitivity responses due to reduced interleukin-10 production predominantly by regulatory B cells. Exp Dermatol 2015; 24:853-6. [PMID: 26121177 DOI: 10.1111/exd.12792] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2015] [Indexed: 01/20/2023]
Abstract
Conflicting observations have been reported concerning the role of CD1d-dependent natural killer T (NKT) cells in contact hypersensitivity (CHS), supporting either a disease-promoting or downregulatory function. We studied the role of NKT cells in CHS by comparing the immune response in CD1d knockout (CD1d KO) and wild-type (Wt) mice after contact allergen exposure. For induction of CHS, C57BL/6 CD1d KO mice (n = 6) and C57BL/6 Wt mice (n = 6) were sensitised with 1% (w/v) dinitrochlorobenzene (DNCB) or vehicle for three consecutive days and subsequently challenged with a single dose of 0.5% DNCB (w/v) on the ears fifteen days later. We demonstrate that CD1d KO mice, as compared with Wt littermates, have more pronounced infiltration of mononuclear cells in the skin (29.1% increase; P < 0.001), lower frequencies of interleukin-10(+) B cells (B(regs) ) in the spleen (53.2% decrease; P < 0.05) and peritoneal cavity (80.8% decrease; P < 0.05) and increased production of interferon-γ (3-fold; P < 0.05) after DNCB sensitisation and challenge, which suggests an important regulatory and protective role of CD1d-dependent NKT cells in CHS in our model, at least in part via regulation of IL-10 producing B(regs) .
Collapse
Affiliation(s)
- Jonas Fjelbye
- The Bartholin Institute, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark
| | - Julie C Antvorskov
- The Bartholin Institute, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark
| | - Karsten Buschard
- The Bartholin Institute, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark
| | - Shohreh Issazadeh-Navikas
- Neuroinflammation Unit, Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
| | - Kåre Engkilde
- The Bartholin Institute, Rigshospitalet, Copenhagen Biocenter, Copenhagen, Denmark.,Department of Dermato-Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
14
|
Gutowska-Owsiak D, Birchall MA, Moots RJ, Christmas SE, Pazmany L. Proliferatory defect of invariant population and accumulation of non-invariant CD1d-restricted natural killer T cells in the joints of RA patients. Mod Rheumatol 2013; 24:434-42. [PMID: 24252027 DOI: 10.3109/14397595.2013.844309] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
OBJECTIVES While numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity. We have evaluated both invariant and non-invariant populations in the blood and synovial fluid from patients to assess feasibility of NKT cell-directed manipulations in RA. METHODS NKT cell populations were quantified by anti-CD4/anti-Vα24 staining and/or CD1d tetramers. Proliferation was measured in cultures of mononuclear cells following stimulations with αGalCer and cytokine secretion determined by multi-bead assay. RESULTS We have confirmed a proliferative defect of iNKT cells in both peripheral blood and synovial fluid from RA patients, but no changes in baseline frequencies. Moreover, we have detected an enlargement of non-invariant cell pool in synovial fluid samples. In addition, we noted an evident Th2 shift following exposure to αGalCer and pronounced IL-6 secretion. CONCLUSIONS While RA patients suffer from defective proliferative responses of invariant NKT cells, non-invariant cells accumulate at the site of inflammation. While stimulation with αGalCer results in reduced TNF-α and increased suppressive IL-10, abundantly produced IL-6 could potentially contribute to the induction of Th17 cells in the joints.
Collapse
Affiliation(s)
- Danuta Gutowska-Owsiak
- Department of Rheumatology, Inflammation Research Unit , School of Clinical Sciences, University of Liverpool , UK
| | | | | | | | | |
Collapse
|
15
|
Zhong MC, Veillette A. The adaptor molecule signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) is essential in mechanisms involving the Fyn tyrosine kinase for induction and progression of collagen-induced arthritis. J Biol Chem 2013; 288:31423-36. [PMID: 24045941 DOI: 10.1074/jbc.m113.473736] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Signaling lymphocytic activation molecule-associated protein (SAP) is an Src homology 2 domain-only adaptor involved in multiple immune cell functions. It has also been linked to immunodeficiencies and autoimmune diseases, such as systemic lupus erythematosus. Here, we examined the role and mechanism of action of SAP in autoimmunity using a mouse model of autoimmune arthritis, collagen-induced arthritis (CIA). We found that SAP was essential for development of CIA in response to collagen immunization. It was also required for production of collagen-specific antibodies, which play a key role in disease pathogenesis. These effects required SAP expression in T cells, not in B cells. In mice immunized with a high dose of collagen, the activity of SAP was nearly independent of its ability to bind the protein tyrosine kinase Fyn and correlated with the capacity of SAP to promote full differentiation of follicular T helper (TFH) cells. However, with a lower dose of collagen, the role of SAP was more dependent on Fyn binding, suggesting that additional mechanisms other than TFH cell differentiation were involved. Further studies suggested that this might be due to a role of the SAP-Fyn interaction in natural killer T cell development through the ability of SAP-Fyn to promote Vav-1 activation. We also found that removal of SAP expression during progression of CIA attenuated disease severity. However, it had no effect on disease when CIA was clinically established. Together, these results indicate that SAP plays an essential role in CIA because of Fyn-independent and Fyn-dependent effects on TFH cells and, possibly, other T cell types.
Collapse
Affiliation(s)
- Ming-Chao Zhong
- From the Laboratory of Molecular Oncology, Clinical Research Institute of Montréal, Montréal, Québec H2W 1R7, Canada
| | | |
Collapse
|
16
|
Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PSC, Ansari AA, Gershwin ME, Akashi K. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol 2012. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
One of the major obstacles in dissecting the mechanism of pathology in human primary biliary cirrhosis (PBC) has been the absence of animal models. Our laboratory has focused on a model in which mice, following immunization with a xenobiotic chemical mimic of the immunodominant autoepitope of the E2 component of pyruvate dehydrogenase complex (PDC-E2), develop autoimmune cholangitis. In particular, following immunization with 2-octynoic acid (a synthetic chemical mimic of lipoic acid-lysine located within the inner domain of PDC-E2) coupled to bovine serum albumin (BSA), several strains of mice develop typical anti-mitochondrial autoantibodies and portal inflammation. The role of innate immune effector cells, such as natural killer (NK) cells and that NK T cells, was studied in this model based on the hypothesis that early events during immunization play an important role in the breakdown of tolerance. We report herein that, following in-vivo depletion of NK and NK T cells, there is a marked suppression of anti-mitochondrial autoantibodies and cytokine production from autoreactive T cells. However, there was no change in the clinical pathology of portal inflammation compared to controls. These data support the hypothesis that there are probably multiple steps in the natural history of PBC, including a role of NK and NK T cells in initiating the breakdown of tolerance. However, the data suggest that adaptive autoimmune effector mechanisms are required for the progression of clinical disease.
Collapse
Affiliation(s)
- S Shimoda
- Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PSC, Ansari AA, Gershwin ME, Akashi K. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol 2012; 168:279-84. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
One of the major obstacles in dissecting the mechanism of pathology in human primary biliary cirrhosis (PBC) has been the absence of animal models. Our laboratory has focused on a model in which mice, following immunization with a xenobiotic chemical mimic of the immunodominant autoepitope of the E2 component of pyruvate dehydrogenase complex (PDC-E2), develop autoimmune cholangitis. In particular, following immunization with 2-octynoic acid (a synthetic chemical mimic of lipoic acid-lysine located within the inner domain of PDC-E2) coupled to bovine serum albumin (BSA), several strains of mice develop typical anti-mitochondrial autoantibodies and portal inflammation. The role of innate immune effector cells, such as natural killer (NK) cells and that NK T cells, was studied in this model based on the hypothesis that early events during immunization play an important role in the breakdown of tolerance. We report herein that, following in-vivo depletion of NK and NK T cells, there is a marked suppression of anti-mitochondrial autoantibodies and cytokine production from autoreactive T cells. However, there was no change in the clinical pathology of portal inflammation compared to controls. These data support the hypothesis that there are probably multiple steps in the natural history of PBC, including a role of NK and NK T cells in initiating the breakdown of tolerance. However, the data suggest that adaptive autoimmune effector mechanisms are required for the progression of clinical disease.
Collapse
Affiliation(s)
- S Shimoda
- Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Kobayashi T, Kawamura H, Kanda Y, Matsumoto H, Saito S, Takeda K, Kawamura T, Abo T. Natural killer T cells suppress zymosan A-mediated granuloma formation in the liver by modulating interferon-γ and interleukin-10. Immunology 2012; 136:86-95. [PMID: 22268994 DOI: 10.1111/j.1365-2567.2012.03562.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Wild-type (WT) and CD1d(-/-) [without natural killer (NK) T cells] mice were treated with zymosan A to induce granuloma formation in the liver. Increased granuloma formation was seen in NKT-less mice on days 7 and 14 after administration. WT mice showed limited granuloma formation, and zymosan A eventually induced NKT cell accumulation as identified by their surface marker (e.g. CD1d-tetramer). Zymosan A augmented the expression of Toll-like receptor 2 on the cell surface of both macrophages and NKT cells. One possible reason for accelerated granuloma formation in NKT-less mice was increased production of interferon- γ (IFN-γ); a theory that was confirmed using IFN-γ(-/-) mice. Also, zymosan A increased interleukin-10 production in WT mice, which suppresses IFN-γ production. Taken together, these results suggest that NKT cells in the liver have the potential to suppress zymosan A-mediated granuloma formation.
Collapse
Affiliation(s)
- Takahiro Kobayashi
- Department of Immunology, Niigata University School of Medicine, Niigata, Japan
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Huang L, Lemos HP, Li L, Li M, Chandler PR, Baban B, McGaha TL, Ravishankar B, Lee JR, Munn DH, Mellor AL. Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. THE JOURNAL OF IMMUNOLOGY 2012; 188:4913-20. [PMID: 22516958 DOI: 10.4049/jimmunol.1103668] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Nanoparticles containing DNA complexed with the cationic polymer polyethylenimine are efficient vehicles to transduce DNA into cells and organisms. DNA/polyethylenimine nanoparticles (DNPs) also elicit rapid and systemic release of proinflammatory cytokines that promote antitumor immunity. In this study, we report that DNPs possess previously unrecognized immunomodulatory attributes due to rapid upregulation of IDO enzyme activity in lymphoid tissues of mice. IDO induction in response to DNP treatment caused dendritic cells and regulatory T cells (Tregs) to acquire potent regulatory phenotypes. As expected, DNP treatment stimulated rapid increase in serum levels of IFN type I (IFN-αβ) and II (IFN-γ), which are both potent IDO inducers. IDO-mediated Treg activation was dependent on IFN type I receptor signaling, whereas IFN-γ receptor signaling was not essential for this response. Moreover, systemic IFN-γ release was caused by TLR9-dependent activation of NK cells, whereas TLR9 signaling was not required for IFN-αβ release. Accordingly, DNPs lacking immunostimulatory TLR9 ligands in DNA stimulated IFN-αβ production, induced IDO, and promoted regulatory outcomes, but did not stimulate potentially toxic, systemic release of IFN-γ. DNP treatment to induce IDO and activate Tregs blocked Ag-specific T cell responses elicited in vivo following immunization and suppressed joint pathology in a model of immune-mediated arthritis. Thus, DNPs lacking TLR9 ligands may be safe and effective reagents to protect healthy tissues from immune-mediated destruction in clinical hyperimmune syndromes.
Collapse
Affiliation(s)
- Lei Huang
- Immunotherapy Center, Georgia Health Sciences University, Augusta, GA 30912, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Li LP, Fang YC, Dong GF, Lin Y, Saito S. Depletion of invariant NKT cells reduces inflammation-induced preterm delivery in mice. THE JOURNAL OF IMMUNOLOGY 2012; 188:4681-9. [PMID: 22467647 DOI: 10.4049/jimmunol.1102628] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
This study sought to determine whether invariant NKT (iNKT) cells play an essential role in inflammation-induced preterm delivery. Preterm delivery and fetal death rates were determined in wild-type (WT) C57BL/6 mice and iNKT cell-deficient Jα18(-/-) mice injected i.p. with LPS. The percentages of decidual immune cells, including activated subsets, and costimulatory molecule expression were analyzed by flow cytometry. Th1 and Th2 cytokine production in the culture supernatants of decidual mononuclear cells was measured by ELISA. To some extent, Jα18(-/-) mice were resistant to LPS-induced preterm delivery. The proportions of decidual CD3(+) and CD49b(+) cells were slightly lower in Jα18(-/-) mice than in WT Jα18(+/+) mice, whereas almost no CD3(+)CD49b(+) cells could be found in Jα18-null mice. The percentages of activated decidual DCs, T cells, and NK cells were significantly lower in LPS-treated Jα18(-/-) mice than in WT mice. The CD40, CD80, and CD86 expression levels on decidual CD11c(+) cells from Jα18(-/-) mice were also significantly lower than in WT mice. Mean concentrations of Th1 cytokines IFN-γ and IL-12p70 in the culture supernatants of decidual mononuclear cells from LPS-treated Jα18(-/-) mice were apparently lower than those of LPS-induced WT mice. Additionally, the proportions of activated CD11c(+) cells, CD3(+) cells, and CD49b(+) cells in LPS-induced preterm delivery mice were strikingly higher in both WT and null mice when compared with the control PBS group and LPS-injected but normally delivered mice. Our results suggest that iNKT cells may play an essential role in inflammation-induced preterm birth.
Collapse
Affiliation(s)
- Li-Ping Li
- Department of Obstetrics and Gynecology, Guangzhou Medical College Affiliated Guangzhou First Municipal People's Hospital, Guangzhou 510180, China
| | | | | | | | | |
Collapse
|
21
|
Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, Miyake S. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. ACTA ACUST UNITED AC 2012; 64:153-61. [PMID: 21904999 DOI: 10.1002/art.33314] [Citation(s) in RCA: 99] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE The function of mucosal-associated invariant T (MAIT) cells remains largely unknown. We previously reported an immunoregulatory role of MAIT cells in an animal model of multiple sclerosis. The aim of this study was to use animal models to determine whether MAIT cells are involved in the pathogenesis of arthritis. METHODS MR1-/- and MR1+/+ DBA/1J mice were immunized with bovine type II collagen (CII) in complete Freund's adjuvant to trigger collagen-induced arthritis (CIA). To assess CII-specific T cell recall responses, lymph node cells from mice with CIA were challenged with CII ex vivo, and cytokine production and proliferation were evaluated. Serum levels of CII-specific antibodies were measured by enzyme-linked immunosorbent assay. Collagen antibody-induced arthritis (CAIA) was induced in MR1-/- and MR1+/+ C57BL/6 mice by injection of anti-CII antibodies followed by injection of lipopolysaccharide. To demonstrate the involvement of MAIT cells in arthritis, we induced CAIA in MR1-/- C57BL/6 mice that had been reconstituted with adoptively transferred MAIT cells. MAIT cell activation in response to cytokine stimulation was investigated. RESULTS The severity of CIA was reduced in MR1-/- DBA/1J mice. However, T and B cell responses to CII were comparable in MR1-/- and MR1+/+ DBA/1J mice. MR1-/- C57BL/6 mice were less susceptible to CAIA, and reconstitution with MAIT cells induced severe arthritis in MR1-/- C57BL/6 mice, demonstrating an effector role of MAIT cells in arthritis. MAIT cells became activated upon stimulation with interleukin-23 (IL-23) or IL-1β in the absence of T cell receptor stimuli. CONCLUSION These results indicate that MAIT cells exacerbate arthritis by enhancing the inflammation.
Collapse
Affiliation(s)
- Asako Chiba
- Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
22
|
Issazadeh-Navikas S. NKT cell self-reactivity: evolutionary master key of immune homeostasis? J Mol Cell Biol 2011; 4:70-8. [PMID: 22167750 DOI: 10.1093/jmcb/mjr035] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Complex immune responses have evolved to protect multicellular organisms against the invasion of pathogens. This has exerted strong developmental pressure for specialized functions that can also limit damage to self-tissue. Two arms of immunity, the innate and adaptive immune systems, have evolved for quick, non-specific immune responses to pathogens and more efficient, long-lasting ones upon specific recognition of recurrent pathogens. Specialized cells have arisen as the sentinels of these functions, including macrophages, natural killer (NK), and T and B-lymphocytes. Interestingly, a population of immune cells that can exert both of these complex functions, NKT cells, not only share common functions but also exhibit shared cell surface markers of cells of both arms of the immune system. These features, in combination with sophisticated maintenance of immune homeostasis, will be discussed. The recent finding of self-peptide reactivity of NKT cells in the context of CD1d, with capacity to regulate multiple autoimmune and inflammatory conditions, motivates the current proposal that self-reactive NKT cells might be the ancestral link between present NK and T cells. Their parallel selection through evolution by higher vertebrates could be related to their central function as master regulators of immune homeostasis that in part is shared with regulatory T cells. Hypothetical views on how self-reactive NKT cells secure such a central role will also be proposed.
Collapse
Affiliation(s)
- Shohreh Issazadeh-Navikas
- Neuroinflammation Unit, Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen Biocentre, Ole Maaløes Vej 5, DK-2200 Copenhagen N, Denmark.
| |
Collapse
|
23
|
Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 2011; 3:1167-84. [PMID: 21995570 PMCID: PMC3230042 DOI: 10.2217/imt.11.117] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express pro- and anti-inflammatory cytokines that influence the type and magnitude of the immune response. Not only do NKT cells regulate the functions of other cell types, but experimental evidence has found NKT cell subsets can modulate the functions of other NKT subsets. Depending on underlying mechanisms, NKT cells can inhibit or exacerbate autoimmunity and malignancy, making them potential targets for disease intervention. NKT cells can respond to foreign and endogenous antigenic glycolipid signals that are expressed during pathogenic invasion or ongoing inflammation, respectively, allowing them to rapidly react to and influence a broad array of diseases. In this article we review the unique development and activation pathways of NKT cells and focus on how these attributes augment or exacerbate autoimmune disorders and malignancy. We also examine the growing evidence that NKT cells are involved in liver inflammatory conditions that can contribute to the development of malignancy.
Collapse
Affiliation(s)
- Jeff J Subleski
- Laboratory of Experimental, Immunology, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
| | - Qun Jiang
- Laboratory of Experimental, Immunology, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
| | - Jonathan M Weiss
- Laboratory of Experimental, Immunology, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
| | - Robert H Wiltrout
- Laboratory of Experimental, Immunology, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA
| |
Collapse
|
24
|
Persson J, Beyer I, Yumul R, Li Z, Kiem HP, Roffler S, Lieber A. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PLoS One 2011; 6:e22303. [PMID: 21779410 PMCID: PMC3136517 DOI: 10.1371/journal.pone.0022303] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2011] [Accepted: 06/23/2011] [Indexed: 11/23/2022] Open
Abstract
Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a novel form of cancer immunotherapy. While preclinical studies in mouse tumor models have shown anti-tumor efficacy of anti-CTLA4 injection or expression, anti-CTLA4 treatment in patients with advanced cancers had disappointing therapeutic benefit. These discrepancies have to be addressed in more adequate pre-clinical models. We employed two tumor models. The first model is based on C57Bl/6 mice and syngeneic TC-1 tumors expressing HPV16 E6/E7. In this model, the HPV antigens are neo-antigens, against which no central tolerance exists. The second model involves mice transgenic for the proto-oncogen neu and syngeneic mouse mammary carcinoma (MMC) cells. In this model tolerance to Neu involves both central and peripheral mechanisms. Anti-CTLA4 delivery as a protein or expression from gene-modified tumor cells were therapeutically efficacious in the non-tolerized TC-1 tumor model, but had no effect in the MMC-model. We also used the two tumor models to test an immuno-gene therapy approach for anti-CTLA4. Recently, we used an approach based on hematopoietic stem cells (HSC) to deliver the relaxin gene to tumors and showed that this approach facilitates pre-existing anti-tumor T-cells to control tumor growth in the MMC tumor model. However, unexpectedly, when used for anti-CTLA4 gene delivery in this study, the HSC-based approach was therapeutically detrimental in both the TC-1 and MMC models. Anti-CTLA4 expression in these models resulted in an increase in the number of intratumoral CD1d+ NKT cells and in the expression of TGF-β1. At the same time, levels of pro-inflammatory cytokines and chemokines, which potentially can support anti-tumor T-cell responses, were lower in tumors of mice that received anti-CTLA4-HSC therapy. The differences in outcomes between the tolerized and non-tolerized models also provide a potential explanation for the low efficacy of CTLA4 blockage approaches in cancer immunotherapy trials.
Collapse
Affiliation(s)
- Jonas Persson
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Ines Beyer
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Roma Yumul
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - ZongYi Li
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
| | - Hans-Peter Kiem
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| | - Steve Roffler
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - André Lieber
- Department of Medicine, University of Washington, Seattle, Washington, United States of America
- Department of Pathology University of Washington, Washington, United States of America
- * E-mail:
| |
Collapse
|
25
|
Hu M, Bassett JHD, Danks L, Howell PGT, Xu K, Spanoudakis E, Kotsianidis I, Boyde A, Williams GR, Horwood N, Roberts IAG, Karadimitris A. Activated invariant NKT cells regulate osteoclast development and function. THE JOURNAL OF IMMUNOLOGY 2011; 186:2910-7. [PMID: 21278350 DOI: 10.4049/jimmunol.1002353] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Invariant NKT (iNKT) cells modulate innate and adaptive immune responses through activation of myeloid dendritic cells and macrophages and via enhanced clonogenicity, differentiation, and egress of their shared myeloid progenitors. Because these same progenitors give rise to osteoclasts (OCs), which also mediate the egress of hematopoietic progenitors and orchestrate bone remodeling, we hypothesized that iNKT cells would extend their myeloid cell regulatory role to the development and function of OCs. In this study, we report that selective activation of iNKT cells by α-galactosylceramide causes myeloid cell egress, enhances OC progenitor and precursor development, modifies the intramedullary kinetics of mature OCs, and enhances their resorptive activity. OC progenitor activity is positively regulated by TNF-α and negatively regulated by IFN-γ, but is IL-4 and IL-17 independent. These data demonstrate a novel role of iNKT cells that couples osteoclastogenesis with myeloid cell egress in conditions of immune activation.
Collapse
Affiliation(s)
- Ming Hu
- Center for Hematology, Hammersmith Hospital, Imperial College London, London W12 0NN, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J Clin Invest 2010; 121:249-64. [PMID: 21157037 DOI: 10.1172/jci43964] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2010] [Accepted: 10/27/2010] [Indexed: 12/13/2022] Open
Abstract
NKT cells in the mouse recognize antigen in the context of the MHC class I-like molecule CD1d and play an important role in peripheral tolerance and protection against autoimmune and other diseases. NKT cells are usually activated by CD1d-presented lipid antigens. However, peptide recognition in the context of CD1 has also been documented, although no self-peptide ligands have been reported to date. Here, we have identified an endogenous peptide that is presented by CD1d to activate mouse NKT cells. This peptide, the immunodominant epitope from mouse collagen type II (mCII707-721), was not associated with either MHC class I or II. Activation of CD1d-restricted mCII707-721-specific NKT cells was induced via TCR signaling and classical costimulation. In addition, mCII707-721-specific NKT cells induced T cell death through Fas/FasL, in an IL-17A-independent fashion. Moreover, mCII707-721-specific NKT cells suppressed a range of in vivo inflammatory conditions, including delayed-type hypersensitivity, antigen-induced airway inflammation, collagen-induced arthritis, and EAE, which were all ameliorated by mCII707-721 vaccination. The findings presented here offer new insight into the intrinsic roles of NKT cells in health and disease. Given the results, endogenous collagen peptide activators of NKT cells may offer promise as novel therapeutics in tissue-specific autoimmune and inflammatory diseases.
Collapse
Affiliation(s)
- Yawei Liu
- Neuroinflammation Unit, Biotech Research and Innovation Centre, University of Copenhagen, Denmark
| | | | | | | | | | | |
Collapse
|